CHEK2 checkpoint kinase 2
Gene ID: 11200, updated on 14-Nov-2024Gene type: protein coding
Also known as: CDS1; CHK2; LFS2; RAD53; TPDS4; hCds1; HuCds1; PP1425
- See all available tests in GTR for this gene
- Go to complete Gene record for CHEK2
- Go to Variation Viewer for CHEK2 variants
Summary
In response to DNA damage and replication blocks, cell cycle progression is halted through the control of critical cell cycle regulators. The protein encoded by this gene is a cell cycle checkpoint regulator and putative tumor suppressor. It contains a forkhead-associated protein interaction domain essential for activation in response to DNA damage and is rapidly phosphorylated in response to replication blocks and DNA damage. When activated, the encoded protein is known to inhibit CDC25C phosphatase, preventing entry into mitosis, and has been shown to stabilize the tumor suppressor protein p53, leading to cell cycle arrest in G1. In addition, this protein interacts with and phosphorylates BRCA1, allowing BRCA1 to restore survival after DNA damage. Mutations in this gene have been linked with Li-Fraumeni syndrome, a highly penetrant familial cancer phenotype usually associated with inherited mutations in TP53. Also, mutations in this gene are thought to confer a predisposition to sarcomas, breast cancer, and brain tumors. This nuclear protein is a member of the CDS1 subfamily of serine/threonine protein kinases. Several transcript variants encoding different isoforms have been found for this gene. [provided by RefSeq, Apr 2012]
Associated conditions
See all available tests in GTR for this gene
Description | Tests |
---|---|
A genome-wide association study of optic disc parameters. GeneReviews: Not available | |
A shared susceptibility locus in PLCE1 at 10q23 for gastric adenocarcinoma and esophageal squamous cell carcinoma. GeneReviews: Not available | |
Bone osteosarcoma | not available |
Genetic variants associated with breast size also influence breast cancer risk. GeneReviews: Not available | |
Genome-wide association analyses of esophageal squamous cell carcinoma in Chinese identify multiple susceptibility loci and gene-environment interactions. GeneReviews: Not available | |
Genome-wide association study identifies multiple susceptibility loci for pancreatic cancer. GeneReviews: Not available | |
Joint analysis of three genome-wide association studies of esophageal squamous cell carcinoma in Chinese populations. GeneReviews: Not available | |
Large-scale genotyping identifies 41 new loci associated with breast cancer risk. GeneReviews: Not available | |
Li-Fraumeni syndrome 2 | not available |
Malignant tumor of prostate MedGen: C0376358GeneReviews: Not available | not available |
Meta-analysis of genome-wide association studies identifies novel loci that influence cupping and the glaucomatous process. GeneReviews: Not available | |
Rare variants of large effect in BRCA2 and CHEK2 affect risk of lung cancer. GeneReviews: Not available |
Copy number response
Description |
---|
Copy number response Triplosensitivity No evidence available (Last evaluated 2020-01-08) ClinGen Genome Curation PageHaploinsufficency Sufficient evidence for dosage pathogenicity (Last evaluated 2020-01-08) ClinGen Genome Curation PagePubMed |
Genomic context
- Location:
- 22q12.1
- Sequence:
- Chromosome: 22; NC_000022.11 (28687743..28741834, complement)
- Total number of exons:
- 21
Variation
Resource | Links for this gene |
---|---|
ClinVar | Variants reported to ClinVar |
dbVar | Studies and variants |
SNP | Variation Viewer for CHEK2 variants |
Genome viewer | Explore NCBI-annotated and select non-NCBI annotated genome assemblies |
- CHEK2 database
- ClinVarRelated medical variations
- dbVarLink from Gene to dbVar
- MedGenRelated information in MedGen
- OMIMLink to related OMIM entry
- PubMed (OMIM)Gene links to PubMed derived from omim_pubmed_cited links
- RefSeq RNAsLink to Nucleotide RefSeq RNAs
- RefSeqGeneLink to Nucleotide RefSeqGenes
- Variation ViewerRelated Variants
IMPORTANT NOTE: NIH does not independently verify information submitted to the GTR; it relies on submitters to provide information that is accurate and not misleading. NIH makes no endorsements of tests or laboratories listed in the GTR. GTR is not a substitute for medical advice. Patients and consumers with specific questions about a genetic test should contact a health care provider or a genetics professional.